FDA Approves Kuvan For Phenylketonuria Treatment

Armen Hareyan's picture

FDA approved Kuvan (sapropterin dihydrochloride), the first drug of its kind approved to slow the effects of a rare genetic disorder that causes mental retardation, smaller brain size, delayed speech and other neurological problems. Tetrahydrobiopterin (BH4)-responsive phenylketonuria or PKU disease occurs in one out of every 12,000 to 15,000 live births in the United States.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.